In this three-part video series, Parexel RBQM experts Amy Kissam-Sands and Tim Audin speak with PharmaVoice editor Taren Grom about ICH guidelines E8 (R1), E6 (R3) and Q9 (R1) and how they will impact clinical development.

Part 1:  ICH E8 (R1) - its impact on the industry and how we can fill the gaps

Part 2: ICH E6 (R3)  - how to implement a proactive risk-management approach and address patient input in study design

Part 3: ICH Q9 (R1) - predictions on what the guidance will cover